{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:45:07Z","timestamp":1791765907873,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01569-w","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:35:38Z","timestamp":1784194538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enabling access to talicabtagene autoleucel in relapsed\/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety"],"prefix":"10.1038","volume":"16","author":[{"given":"Atharva","family":"Karulkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasmukh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Sidharthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Bhurani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Melinkeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan Kumar","family":"Boyella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esha","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9776-6920","authenticated-orcid":false,"given":"Jayachandran","family":"P. K.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3051-4112","authenticated-orcid":false,"given":"Chandran","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5769-8073","authenticated-orcid":false,"given":"Rahul","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9754-0182","authenticated-orcid":false,"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingaraj","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh Reddy","family":"Boya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Abhinav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devanshi","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smrithi","family":"Ravikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashree","family":"Thorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of Real World Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Baheti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Charan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Lahoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amul","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Aribandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshul","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Chakrapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijay P.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Badarkhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannan","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kripa","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra","family":"Anukonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmaja","family":"Lokireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parathan","family":"Karunakaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash Singh","family":"Shekhawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Samal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. V.","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumesh","family":"Chandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sainath","family":"Bhethanabhotla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Tulpule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharat","family":"Damodar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Vaniyath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunu","family":"Cyriac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Chiraniya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Rajshekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasu Babu","family":"Goli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velu","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishwanath","family":"Sathyanarayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Sadique","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuktam","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Gera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manivasagam","family":"Sundharam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreshtha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrin","family":"Firfiray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranali","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juber","family":"Pendhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Beher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Hotchandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupa","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Purwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-5226","authenticated-orcid":false,"given":"Terry","family":"Fry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-4914","authenticated-orcid":false,"given":"Sattva","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3509-5682","authenticated-orcid":false,"given":"Manju","family":"Sengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3319-0309","authenticated-orcid":false,"given":"Rahul","family":"Purwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"1569_CR1","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1182\/blood-2019-127091","volume":"134","author":"P Ganesan","year":"2019","unstructured":"Ganesan P, Jain H, Bagal B, Subramanian PG, George B, Korula A, et al. Outcomes in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL): a report from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC). Blood. 2019;134:1306.","journal-title":"Blood"},{"key":"1569_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.922370","volume":"12","author":"L Kumar","year":"2022","unstructured":"Kumar L, Kn N, Gujral S, Kulkarni P, Stockler MR, Nair R. Real world outcomes of lymphoma from India. Front Oncol. 2022;12:922370.","journal-title":"Front Oncol"},{"key":"1569_CR3","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. Global cancer observatory: cancer today (version 1.1). Lyon, France: International Agency for Research on Cancer; 2024. URL: https:\/\/gco.iarc who int\/today 2024."},{"key":"1569_CR4","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.clml.2020.08.023","volume":"21","author":"VS Radhakrishnan","year":"2021","unstructured":"Radhakrishnan VS, Agrawal N, Bagal B, Patel I. Systematic review of the burden and treatment patterns of adult and adolescent acute lymphoblastic leukemia in India: comprehending the challenges in an emerging economy. Clin Lymphoma Myeloma Leuk. 2021;21:e85\u2013e98.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1569_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1171568","volume":"13","author":"V Mathews","year":"2023","unstructured":"Mathews V, Korula A, Chakrapani A, Bhurani D, Bhattacharyya J, Sengar M, et al. Management of B-cell lineage acute lymphoblastic leukemia: expert opinion from an Indian panel via Delphi consensus method. Front Oncol. 2023;13:1171568.","journal-title":"Front Oncol"},{"key":"1569_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12098-023-04635-4","volume":"91","author":"J Sidhu","year":"2024","unstructured":"Sidhu J, Gogoi MP, Krishnan S, Saha V. Relapsed acute lymphoblastic leukemia. Indian J Pediatr. 2024;91:158\u201367.","journal-title":"Indian J Pediatr"},{"key":"1569_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/d41586-024-00809-y","volume":"627","author":"S Mallapaty","year":"2024","unstructured":"Mallapaty S. Cutting-edge CAR-T cancer therapy is now made in India-at one-tenth the cost. Nature. 2024;627:709\u201310.","journal-title":"Nature"},{"key":"1569_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40291-024-00719-9","volume":"28","author":"T Nie","year":"2024","unstructured":"Nie T. Talicabtagene autoleucel: first approval. Mol Diagn Ther. 2024;28:495\u20139.","journal-title":"Mol Diagn Ther"},{"key":"1569_CR9","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1016\/S2352-3026(25)00040-7","volume":"12","author":"L Paruzzo","year":"2025","unstructured":"Paruzzo L, Ruella M. CAR T-cell therapy in LMICs: approval of talicabtagene autoleucel in India. The Lancet Haematology. 2025;12:e236\u20138.","journal-title":"The Lancet Haematology"},{"key":"1569_CR10","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1016\/S2352-3026(24)00377-6","volume":"12","author":"H Jain","year":"2025","unstructured":"Jain H, Karulkar A, Kalra D, Ravikumar S, Shah S, Pendhari A, et al. Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1\/2 study. The Lancet Haematology. 2025;12:e282\u201393.","journal-title":"The Lancet Haematology"},{"key":"1569_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2023-177594","volume":"142","author":"A Karulkar","year":"2023","unstructured":"Karulkar A, Jaiswal AK, Khan A, Kalra D, Ravikumar S, Ghandade N, et al. Excellent safety profile of a low-cost novel humanized CD19 CAR T-cell therapy, actalycabtagene autoleucel: potential impact on access and feasibility. Blood. 2023;142:257.","journal-title":"Blood"},{"key":"1569_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/14737140.2025.2501744","volume":"25","author":"H Hotchandani","year":"2025","unstructured":"Hotchandani H, Sengar M, Shetty A, John A, Karulkar A, Kalra D, et al. Implementation of a CAR-T cell therapy program in India. Expert Rev Anticancer Ther. 2025;25:599\u2013608.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1569_CR13","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1016\/S1470-2045(24)00736-8","volume":"26","author":"ADJ Pearson","year":"2025","unstructured":"Pearson ADJ, Rossig C, Mackall CL, Shah NN, Baruchel A, Daems S, et al. New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis. Lancet Oncol. 2025;26:e214\u201324.","journal-title":"Lancet Oncol"},{"key":"1569_CR14","first-page":"438","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transpl Cell Ther. 2023;29:438\u2013e1.","journal-title":"Transpl Cell Ther"},{"key":"1569_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","volume":"9","author":"A Looka","year":"2025","unstructured":"Looka A, Qualls DA, Matthews D, Redd RA, Sakellis C, Duffy C, et al. A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma. Blood Adv. 2025;9:455\u201362.","journal-title":"Blood Adv"},{"key":"1569_CR16","first-page":"1082","volume":"30","author":"B Hu","year":"2024","unstructured":"Hu B, Vaidya R, Ahmed F, Ehsan H, Moyo TK, Jacobs RW, et al. Real-world analysis of barriers to timely administration of chimeric antigen receptor T cell (CAR T) therapy in diffuse large B-cell lymphoma. Transpl Cell Ther. 2024;30:1082\u2013e1.","journal-title":"Transpl Cell Ther"},{"key":"1569_CR17","doi-asserted-by":"crossref","unstructured":"Desch\u00eanes-Simard X, Bromberg M, Devlin SM, Gonen M, Beyar-Katz O, Ip A, et al. Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma. Blood Adv. 2025;9:5571\u201384.","DOI":"10.1182\/bloodadvances.2025016778"},{"key":"1569_CR18","doi-asserted-by":"crossref","unstructured":"John S, Curran KJ, Hall EM, Keating AK, Baumeister SH, Nikiforow S, et al. Real-world data for tisagenlecleucel in patients with R\/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Adv. 2025;9:5249\u201362.","DOI":"10.1182\/bloodadvances.2025015881"},{"key":"1569_CR19","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu Z-H, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4:5414\u201324.","journal-title":"Blood Adv"},{"key":"1569_CR20","first-page":"558","volume":"43","author":"GW Roloff","year":"2025","unstructured":"Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, et al. Outcomes after brexucabtagene autoleucel administered as a standard therapy for adults with relapsed\/refractory B-cell. ALL. 2025;43:558\u201366.","journal-title":"ALL"},{"key":"1569_CR21","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1182\/bloodadvances.2024013747","volume":"8","author":"I Aldoss","year":"2024","unstructured":"Aldoss I, Roloff GW, Faramand R, Kopmar NE, Lin C, Advani AS, et al. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024;8:6139\u201347.","journal-title":"Blood Adv"},{"key":"1569_CR22","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1182\/bloodadvances.2024014846","volume":"9","author":"H Lust","year":"2025","unstructured":"Lust H, Schultz LM, Kwon S, Roloff GW, Aldoss I, Baggott C, et al. Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy. Blood Adv. 2025;9:2763\u201372.","journal-title":"Blood Adv"},{"key":"1569_CR23","first-page":"77","volume":"30","author":"CA Jacobson","year":"2024","unstructured":"Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, et al. Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis. Transpl Cell Ther. 2024;30:77\u2013e1.","journal-title":"Transpl Cell Ther"},{"key":"1569_CR24","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28:2145\u201354.","journal-title":"Nat Med"},{"key":"1569_CR25","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/bloodadvances.2024014164","volume":"9","author":"PA Riedell","year":"2025","unstructured":"Riedell PA, Grady CB, Nastoupil LJ, Luna A, Ahmed N, Maziarz RT, et al. Lisocabtagene maraleucel for relapsed\/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv. 2025;9:1232\u201341.","journal-title":"Blood Adv"},{"key":"1569_CR26","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1182\/blood-2023-185107","volume":"142","author":"NE Kopmar","year":"2023","unstructured":"Kopmar NE, Gooley T, Roloff GW, Aldoss I, Lin C, Dekker SE, et al. Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed\/Refractory (R\/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): results from a Multicenter Real-World Outcomes Study. Blood. 2023;142:522.","journal-title":"Blood"},{"key":"1569_CR27","doi-asserted-by":"crossref","unstructured":"McNerney KO, Schultz LM. Tisagenlecleucel in practice: Real-world lessons in pediatric and young adult B-ALL. Transplant Cell Ther. 2025;31:351\u2013e1.","DOI":"10.1016\/j.jtct.2025.02.016"},{"key":"1569_CR28","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1182\/blood.2023022922","volume":"145","author":"A Rampotas","year":"2025","unstructured":"Rampotas A, Roddie C. The present and future of CAR T-cell therapy for adult B-cell ALL. Blood. 2025;145:1485\u201397.","journal-title":"Blood"},{"key":"1569_CR29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41409-025-02519-z","volume":"60","author":"M Corona","year":"2025","unstructured":"Corona M, Ip A, Brown S, Luna A, Khatib H, Flynn JR, et al. Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma. Bone Marrow Transpl. 2025;60:491\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"1569_CR30","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol. 2021;39:1650\u20139.","journal-title":"J Clin Oncol"},{"key":"1569_CR31","first-page":"31","volume":"28","author":"JC Molina","year":"2022","unstructured":"Molina JC, Steinberg SM, Yates B, Lee DW, Little L, Mackall CL, et al. Factors impacting overall and event-free survival following post-chimeric antigen receptor T cell consolidative hematopoietic stem cell transplantation. Transpl Cell Ther. 2022;28:31\u2013e1.","journal-title":"Transpl Cell Ther"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01569-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01569-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01569-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T23:47:52Z","timestamp":1791762472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01569-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1569"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01569-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HJ reports having received funding to the institute from ImmunoACT for conduct of the study. AK and RP are an equity holder and member of Board of Directors and advisory committee of ImmunoACT. AK and RP are patent holder for the novel humanized anti-CD19 CAR. TF received grants from NIH, Department of Defense and Leukemia Lymphoma society. TF received consulting fees from Sana Biotechnology. TF has a patent with University of Colorado Anchutz Medical Campus for CAR-T cell. TF is part of the committee for scientific affairs in American Society of Hematology. TF holds stocks in San Biotechnology. NNS receives royalties for CD22 CAR (CARGO Therapeutics). NNS is part of the scientific advisory board of ImmunoACT, CARGO and VOR. SN reports having received funding to the institute from Kite\/Gilead, BMS, Allogene, Precision Biosciences, Adicet Bio, Sana Biotechnology, Cargo Therapeutics. SN has received consulting fees from Kite\/Gilead, Sellas Life Sciences, Athenex, Allogene, Incyte, Adicet Bio, BMS, Bluebird Bio, Fosun Kite, Sana Biotechnology, Caribou, Astellas Pharma, Morphosys, Janssen, Chimagen, ImmunoACT, Orna Therapeutics, Takeda, Synthekine, Carsgen, Appia Bio, GlaxoSmithKline, Galapagos, ModeX Therapeutics, Jazz Pharmaceuticals. SN has received honoraria for lectures from MJH Life Sciences, PeerView, and MD. Education. SN has patents related to cell therapy and holds stocks in Longbow Immunotherapy. All the other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"177"}}